11/11
10:18 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
11/11
10:18 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
11/11
09:52 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
11/11
09:52 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
11/11
08:14 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
11/11
07:03 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/7
08:20 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating.
11/7
08:20 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating.
11/6
06:55 pm
fdmt
4D Molecular upgraded to Equal Weight from Underweight at Morgan Stanley
Medium
Report
4D Molecular upgraded to Equal Weight from Underweight at Morgan Stanley
11/6
06:55 pm
fdmt
4D Molecular upgraded to Equal Weight from Underweight at Morgan Stanley
Medium
Report
4D Molecular upgraded to Equal Weight from Underweight at Morgan Stanley
10/31
11:03 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
10/21
10:50 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $26.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $26.00 price target on the stock.
10/21
10:50 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $26.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $26.00 price target on the stock.
10/21
10:26 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
10/21
10:26 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT